Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis Clinical Trial

Official title: A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the effects of Ceftazidime Avibactam compared to Doripenem for treating hospitalized patients with complicated urinary tract infections, including acute pyelonephritis

Clinical Trial Description

A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam (CAZ-AVI, formerly CAZ104) Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, With a Gram Negative Pathogen in Hospitalized Adults ;

Related Conditions & MeSH terms

• Communicable Diseases
• Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
• Infection
• Pyelonephritis
• Urinary Tract Infections

• NCT number: NCT01599806
• Study type: Interventional
• Source: Pfizer
• Status: Completed
• Phase: Phase 3
• Start date: October 2012
• Completion date: August 2014